Gregory M. M. Videtic, MD, CM

home / authors / gregory-m-m-videtic-md-cm

Articles

ASTRO 2017: Long-Term Data Support Single SBRT Dose in Certain Early Lung Cancers

October 5th 2017

This video reviews long-term results of the NRG Oncology RTOG 0915 trial, a randomized phase II study that compared stereotactic body radiation therapy delivered in one fraction vs four fractions for stage I peripheral non–small-cell lung cancer patients with unresectable disease.

ACR Appropriateness Criteria® Nonsurgical Treatment for Locally Advanced Non–Small-Cell Lung Cancer: Good Performance Status/Definitive Intent

Joe Yujiao Chang, MD, PhD;Larry L. Kestin, MD;R. Bryan Barriger, MD;Indrin J. Chetty, PhD;Mark E. Ginsburg, MD;Sanath Kumar, MD;Billy W. Loo, Jr, MD, PhD;Benjamin Movsas, MD;Andreas Rimner, MD;Kenneth E. Rosenzweig, MD;Thomas E. Stinchcombe, MD;Gregory M. M. Videtic, MD, CM;Henning Willers, MD

August 15th 2014

The treatment of inoperable stage III non–small-cell lung cancer (NSCLC) remains a challenge due to high rates of distant metastasis, local recurrence, and toxicity associated with definitive therapy.